ONCOLYTICS BIOTECH INC

Analysis for Ticker: ONCY

Oncolytics Biotech Inc is a clinical stage company that says it develops an intravenous therapy called pelareorep to turn cold tumors into hot ones to fight cancer. The reality is that since its birth in 1998, this operation has functioned as a machine to move cash from the public into private hands, accumulating a deficit of 429,5$ million without ever selling a product. The math is a disaster because the company does not exist to cure patients, but to manufacture and sell its own stock to pay for a massive office and expensive bosses. Imagine a lemonade stand that never sells lemonade but survives only by selling pieces of the stand to new kids while the original owners take all the lunch money for themselves. The destruction began to accelerate years ago, but the recent records show a terminal trajectory. In 2023, the former chief executive officer Matthew Coffey took over 2,2$ million Canadian dollars from the company. By 2024, the company reported a net loss of 22,8$ million, yet Matthew Coffey still took over 1$ million while the chief financial officer Kirk Look and chief medical officer Thomas Charles Heineman each extracted over 1$ million. The shareholders were paying for these checks while the stock performance fell from a baseline of 100 in 2019 to just 21,63 by the end of 2024.